Industry Research Reports

Home > Reports > Service & Software > Personalizing Cancer Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Personalizing Cancer Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Service & Software

Published: 2024-01-24

Pages: 135 Pages

Report ld: 2343093

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

The global market for Personalizing Cancer Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Personalizing Cancer Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Personalizing Cancer Drugs by region & country, by Type, and by Application.

The Personalizing Cancer Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Personalizing Cancer Drugs.

Market Segmentation

Report Metric
Details
Report Title
Personalizing Cancer Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Global Personalizing Cancer Drugs Companies Covered
Bayer, GlaxoSmithKline, Novartis, Sanofi, Pfizer, Amgen, Merck, Bristol-Myers Squibb, Celgene Corporation, Ariad Pharmaceuticals, Eli Lilly, Hoffmann-La Roche, Boehringer Ingelheim, Johnson and Johnson, Teva Pharmaceuticals
Global Personalizing Cancer Drugs Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Personalizing Cancer Drugs Market, Segment by Type
Immunotherapy

Targeted Therapy

Chemotherapy

Hormone Therapy

Others
Global Personalizing Cancer Drugs Market, Segment by Application
Breast Cancer

Blood Cancer

Gastrointestinal Cancer

Prostate Cancer

Skin Cancer

Lung Cancer

Others
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Personalizing Cancer Drugs manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Personalizing Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Personalizing Cancer Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Personalizing Cancer Drugs Product Introduction
    1.2 Global Personalizing Cancer Drugs Market Size Forecast
    1.3 Personalizing Cancer Drugs Market Trends & Drivers
        1.3.1 Personalizing Cancer Drugs Industry Trends
        1.3.2 Personalizing Cancer Drugs Market Drivers & Opportunity
        1.3.3 Personalizing Cancer Drugs Market Challenges
        1.3.4 Personalizing Cancer Drugs Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Personalizing Cancer Drugs Players Revenue Ranking (2023)
    2.2 Global Personalizing Cancer Drugs Revenue by Company (2019-2024)
    2.3 Key Companies Personalizing Cancer Drugs Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Personalizing Cancer Drugs Product Offered
    2.5 Key Companies Time to Begin Mass Production of Personalizing Cancer Drugs
    2.6 Personalizing Cancer Drugs Market Competitive Analysis
        2.6.1 Personalizing Cancer Drugs Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Personalizing Cancer Drugs Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Personalizing Cancer Drugs as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Immunotherapy
        3.1.2 Targeted Therapy
        3.1.3 Chemotherapy
        3.1.4 Hormone Therapy
        3.1.5 Others
    3.2 Global Personalizing Cancer Drugs Sales Value by Type
        3.2.1 Global Personalizing Cancer Drugs Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Personalizing Cancer Drugs Sales Value, by Type (2019-2030)
        3.2.3 Global Personalizing Cancer Drugs Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Breast Cancer
        4.1.2 Blood Cancer
        4.1.3 Gastrointestinal Cancer
        4.1.4 Prostate Cancer
        4.1.5 Skin Cancer
        4.1.6 Lung Cancer
        4.1.7 Others
    4.2 Global Personalizing Cancer Drugs Sales Value by Application
        4.2.1 Global Personalizing Cancer Drugs Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Personalizing Cancer Drugs Sales Value, by Application (2019-2030)
        4.2.3 Global Personalizing Cancer Drugs Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Personalizing Cancer Drugs Sales Value by Region
        5.1.1 Global Personalizing Cancer Drugs Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Personalizing Cancer Drugs Sales Value by Region (2019-2024)
        5.1.3 Global Personalizing Cancer Drugs Sales Value by Region (2025-2030)
        5.1.4 Global Personalizing Cancer Drugs Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Personalizing Cancer Drugs Sales Value, 2019-2030
        5.2.2 North America Personalizing Cancer Drugs Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Personalizing Cancer Drugs Sales Value, 2019-2030
        5.3.2 Europe Personalizing Cancer Drugs Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Personalizing Cancer Drugs Sales Value, 2019-2030
        5.4.2 Asia Pacific Personalizing Cancer Drugs Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Personalizing Cancer Drugs Sales Value, 2019-2030
        5.5.2 South America Personalizing Cancer Drugs Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Personalizing Cancer Drugs Sales Value, 2019-2030
        5.6.2 Middle East & Africa Personalizing Cancer Drugs Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Personalizing Cancer Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Personalizing Cancer Drugs Sales Value
    6.3 United States
        6.3.1 United States Personalizing Cancer Drugs Sales Value, 2019-2030
        6.3.2 United States Personalizing Cancer Drugs Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Personalizing Cancer Drugs Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Personalizing Cancer Drugs Sales Value, 2019-2030
        6.4.2 Europe Personalizing Cancer Drugs Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Personalizing Cancer Drugs Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Personalizing Cancer Drugs Sales Value, 2019-2030
        6.5.2 China Personalizing Cancer Drugs Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Personalizing Cancer Drugs Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Personalizing Cancer Drugs Sales Value, 2019-2030
        6.6.2 Japan Personalizing Cancer Drugs Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Personalizing Cancer Drugs Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Personalizing Cancer Drugs Sales Value, 2019-2030
        6.7.2 South Korea Personalizing Cancer Drugs Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Personalizing Cancer Drugs Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Personalizing Cancer Drugs Sales Value, 2019-2030
        6.8.2 Southeast Asia Personalizing Cancer Drugs Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Personalizing Cancer Drugs Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Personalizing Cancer Drugs Sales Value, 2019-2030
        6.9.2 India Personalizing Cancer Drugs Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Personalizing Cancer Drugs Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Bayer
        7.1.1 Bayer Profile
        7.1.2 Bayer Main Business
        7.1.3 Bayer Personalizing Cancer Drugs Products, Services and Solutions
        7.1.4 Bayer Personalizing Cancer Drugs Revenue (US$ Million) & (2019-2024)
        7.1.5 Bayer Recent Developments
    7.2 GlaxoSmithKline
        7.2.1 GlaxoSmithKline Profile
        7.2.2 GlaxoSmithKline Main Business
        7.2.3 GlaxoSmithKline Personalizing Cancer Drugs Products, Services and Solutions
        7.2.4 GlaxoSmithKline Personalizing Cancer Drugs Revenue (US$ Million) & (2019-2024)
        7.2.5 GlaxoSmithKline Recent Developments
    7.3 Novartis
        7.3.1 Novartis Profile
        7.3.2 Novartis Main Business
        7.3.3 Novartis Personalizing Cancer Drugs Products, Services and Solutions
        7.3.4 Novartis Personalizing Cancer Drugs Revenue (US$ Million) & (2019-2024)
        7.3.5 Sanofi Recent Developments
    7.4 Sanofi
        7.4.1 Sanofi Profile
        7.4.2 Sanofi Main Business
        7.4.3 Sanofi Personalizing Cancer Drugs Products, Services and Solutions
        7.4.4 Sanofi Personalizing Cancer Drugs Revenue (US$ Million) & (2019-2024)
        7.4.5 Sanofi Recent Developments
    7.5 Pfizer
        7.5.1 Pfizer Profile
        7.5.2 Pfizer Main Business
        7.5.3 Pfizer Personalizing Cancer Drugs Products, Services and Solutions
        7.5.4 Pfizer Personalizing Cancer Drugs Revenue (US$ Million) & (2019-2024)
        7.5.5 Pfizer Recent Developments
    7.6 Amgen
        7.6.1 Amgen Profile
        7.6.2 Amgen Main Business
        7.6.3 Amgen Personalizing Cancer Drugs Products, Services and Solutions
        7.6.4 Amgen Personalizing Cancer Drugs Revenue (US$ Million) & (2019-2024)
        7.6.5 Amgen Recent Developments
    7.7 Merck
        7.7.1 Merck Profile
        7.7.2 Merck Main Business
        7.7.3 Merck Personalizing Cancer Drugs Products, Services and Solutions
        7.7.4 Merck Personalizing Cancer Drugs Revenue (US$ Million) & (2019-2024)
        7.7.5 Merck Recent Developments
    7.8 Bristol-Myers Squibb
        7.8.1 Bristol-Myers Squibb Profile
        7.8.2 Bristol-Myers Squibb Main Business
        7.8.3 Bristol-Myers Squibb Personalizing Cancer Drugs Products, Services and Solutions
        7.8.4 Bristol-Myers Squibb Personalizing Cancer Drugs Revenue (US$ Million) & (2019-2024)
        7.8.5 Bristol-Myers Squibb Recent Developments
    7.9 Celgene Corporation
        7.9.1 Celgene Corporation Profile
        7.9.2 Celgene Corporation Main Business
        7.9.3 Celgene Corporation Personalizing Cancer Drugs Products, Services and Solutions
        7.9.4 Celgene Corporation Personalizing Cancer Drugs Revenue (US$ Million) & (2019-2024)
        7.9.5 Celgene Corporation Recent Developments
    7.10 Ariad Pharmaceuticals
        7.10.1 Ariad Pharmaceuticals Profile
        7.10.2 Ariad Pharmaceuticals Main Business
        7.10.3 Ariad Pharmaceuticals Personalizing Cancer Drugs Products, Services and Solutions
        7.10.4 Ariad Pharmaceuticals Personalizing Cancer Drugs Revenue (US$ Million) & (2019-2024)
        7.10.5 Ariad Pharmaceuticals Recent Developments
    7.11 Eli Lilly
        7.11.1 Eli Lilly Profile
        7.11.2 Eli Lilly Main Business
        7.11.3 Eli Lilly Personalizing Cancer Drugs Products, Services and Solutions
        7.11.4 Eli Lilly Personalizing Cancer Drugs Revenue (US$ Million) & (2019-2024)
        7.11.5 Eli Lilly Recent Developments
    7.12 Hoffmann-La Roche
        7.12.1 Hoffmann-La Roche Profile
        7.12.2 Hoffmann-La Roche Main Business
        7.12.3 Hoffmann-La Roche Personalizing Cancer Drugs Products, Services and Solutions
        7.12.4 Hoffmann-La Roche Personalizing Cancer Drugs Revenue (US$ Million) & (2019-2024)
        7.12.5 Hoffmann-La Roche Recent Developments
    7.13 Boehringer Ingelheim
        7.13.1 Boehringer Ingelheim Profile
        7.13.2 Boehringer Ingelheim Main Business
        7.13.3 Boehringer Ingelheim Personalizing Cancer Drugs Products, Services and Solutions
        7.13.4 Boehringer Ingelheim Personalizing Cancer Drugs Revenue (US$ Million) & (2019-2024)
        7.13.5 Boehringer Ingelheim Recent Developments
    7.14 Johnson and Johnson
        7.14.1 Johnson and Johnson Profile
        7.14.2 Johnson and Johnson Main Business
        7.14.3 Johnson and Johnson Personalizing Cancer Drugs Products, Services and Solutions
        7.14.4 Johnson and Johnson Personalizing Cancer Drugs Revenue (US$ Million) & (2019-2024)
        7.14.5 Johnson and Johnson Recent Developments
    7.15 Teva Pharmaceuticals
        7.15.1 Teva Pharmaceuticals Profile
        7.15.2 Teva Pharmaceuticals Main Business
        7.15.3 Teva Pharmaceuticals Personalizing Cancer Drugs Products, Services and Solutions
        7.15.4 Teva Pharmaceuticals Personalizing Cancer Drugs Revenue (US$ Million) & (2019-2024)
        7.15.5 Teva Pharmaceuticals Recent Developments

 8 Industry Chain Analysis
    8.1 Personalizing Cancer Drugs Industrial Chain
    8.2 Personalizing Cancer Drugs Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Personalizing Cancer Drugs Sales Model
        8.5.2 Sales Channel
        8.5.3 Personalizing Cancer Drugs Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Personalizing Cancer Drugs Market Trends
    Table 2. Personalizing Cancer Drugs Market Drivers & Opportunity
    Table 3. Personalizing Cancer Drugs Market Challenges
    Table 4. Personalizing Cancer Drugs Market Restraints
    Table 5. Global Personalizing Cancer Drugs Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Personalizing Cancer Drugs Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Personalizing Cancer Drugs Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Personalizing Cancer Drugs Product Type
    Table 9. Key Companies Time to Begin Mass Production of Personalizing Cancer Drugs
    Table 10. Global Personalizing Cancer Drugs Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Personalizing Cancer Drugs as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Personalizing Cancer Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Personalizing Cancer Drugs Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Personalizing Cancer Drugs Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Personalizing Cancer Drugs Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Personalizing Cancer Drugs Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Personalizing Cancer Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Personalizing Cancer Drugs Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Personalizing Cancer Drugs Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Personalizing Cancer Drugs Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Personalizing Cancer Drugs Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Personalizing Cancer Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Personalizing Cancer Drugs Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Personalizing Cancer Drugs Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Personalizing Cancer Drugs Sales Value by Region (2019-2024) & (%)
    Table 27. Global Personalizing Cancer Drugs Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Personalizing Cancer Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Personalizing Cancer Drugs Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Personalizing Cancer Drugs Sales Value, (2025-2030) & (US$ Million)
    Table 31. Bayer Basic Information List
    Table 32. Bayer Description and Business Overview
    Table 33. Bayer Personalizing Cancer Drugs Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Personalizing Cancer Drugs Business of Bayer (2019-2024)
    Table 35. Bayer Recent Developments
    Table 36. GlaxoSmithKline Basic Information List
    Table 37. GlaxoSmithKline Description and Business Overview
    Table 38. GlaxoSmithKline Personalizing Cancer Drugs Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Personalizing Cancer Drugs Business of GlaxoSmithKline (2019-2024)
    Table 40. GlaxoSmithKline Recent Developments
    Table 41. Novartis Basic Information List
    Table 42. Novartis Description and Business Overview
    Table 43. Novartis Personalizing Cancer Drugs Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Personalizing Cancer Drugs Business of Novartis (2019-2024)
    Table 45. Novartis Recent Developments
    Table 46. Sanofi Basic Information List
    Table 47. Sanofi Description and Business Overview
    Table 48. Sanofi Personalizing Cancer Drugs Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Personalizing Cancer Drugs Business of Sanofi (2019-2024)
    Table 50. Sanofi Recent Developments
    Table 51. Pfizer Basic Information List
    Table 52. Pfizer Description and Business Overview
    Table 53. Pfizer Personalizing Cancer Drugs Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Personalizing Cancer Drugs Business of Pfizer (2019-2024)
    Table 55. Pfizer Recent Developments
    Table 56. Amgen Basic Information List
    Table 57. Amgen Description and Business Overview
    Table 58. Amgen Personalizing Cancer Drugs Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Personalizing Cancer Drugs Business of Amgen (2019-2024)
    Table 60. Amgen Recent Developments
    Table 61. Merck Basic Information List
    Table 62. Merck Description and Business Overview
    Table 63. Merck Personalizing Cancer Drugs Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Personalizing Cancer Drugs Business of Merck (2019-2024)
    Table 65. Merck Recent Developments
    Table 66. Bristol-Myers Squibb Basic Information List
    Table 67. Bristol-Myers Squibb Description and Business Overview
    Table 68. Bristol-Myers Squibb Personalizing Cancer Drugs Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Personalizing Cancer Drugs Business of Bristol-Myers Squibb (2019-2024)
    Table 70. Bristol-Myers Squibb Recent Developments
    Table 71. Celgene Corporation Basic Information List
    Table 72. Celgene Corporation Description and Business Overview
    Table 73. Celgene Corporation Personalizing Cancer Drugs Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Personalizing Cancer Drugs Business of Celgene Corporation (2019-2024)
    Table 75. Celgene Corporation Recent Developments
    Table 76. Ariad Pharmaceuticals Basic Information List
    Table 77. Ariad Pharmaceuticals Description and Business Overview
    Table 78. Ariad Pharmaceuticals Personalizing Cancer Drugs Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Personalizing Cancer Drugs Business of Ariad Pharmaceuticals (2019-2024)
    Table 80. Ariad Pharmaceuticals Recent Developments
    Table 81. Eli Lilly Basic Information List
    Table 82. Eli Lilly Description and Business Overview
    Table 83. Eli Lilly Personalizing Cancer Drugs Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Personalizing Cancer Drugs Business of Eli Lilly (2019-2024)
    Table 85. Eli Lilly Recent Developments
    Table 86. Hoffmann-La Roche Basic Information List
    Table 87. Hoffmann-La Roche Description and Business Overview
    Table 88. Hoffmann-La Roche Personalizing Cancer Drugs Products, Services and Solutions
    Table 89. Revenue (US$ Million) in Personalizing Cancer Drugs Business of Hoffmann-La Roche (2019-2024)
    Table 90. Hoffmann-La Roche Recent Developments
    Table 91. Boehringer Ingelheim Basic Information List
    Table 92. Boehringer Ingelheim Description and Business Overview
    Table 93. Boehringer Ingelheim Personalizing Cancer Drugs Products, Services and Solutions
    Table 94. Revenue (US$ Million) in Personalizing Cancer Drugs Business of Boehringer Ingelheim (2019-2024)
    Table 95. Boehringer Ingelheim Recent Developments
    Table 96. Johnson and Johnson Basic Information List
    Table 97. Johnson and Johnson Description and Business Overview
    Table 98. Johnson and Johnson Personalizing Cancer Drugs Products, Services and Solutions
    Table 99. Revenue (US$ Million) in Personalizing Cancer Drugs Business of Johnson and Johnson (2019-2024)
    Table 100. Johnson and Johnson Recent Developments
    Table 101. Teva Pharmaceuticals Basic Information List
    Table 102. Teva Pharmaceuticals Description and Business Overview
    Table 103. Teva Pharmaceuticals Personalizing Cancer Drugs Products, Services and Solutions
    Table 104. Revenue (US$ Million) in Personalizing Cancer Drugs Business of Teva Pharmaceuticals (2019-2024)
    Table 105. Teva Pharmaceuticals Recent Developments
    Table 106. Key Raw Materials Lists
    Table 107. Raw Materials Key Suppliers Lists
    Table 108. Personalizing Cancer Drugs Downstream Customers
    Table 109. Personalizing Cancer Drugs Distributors List
    Table 110. Research Programs/Design for This Report
    Table 111. Key Data Information from Secondary Sources
    Table 112. Key Data Information from Primary Sources
    Table 113. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Personalizing Cancer Drugs Product Picture
    Figure 2. Global Personalizing Cancer Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Personalizing Cancer Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 4. Personalizing Cancer Drugs Report Years Considered
    Figure 5. Global Personalizing Cancer Drugs Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Personalizing Cancer Drugs Revenue in 2023
    Figure 7. Personalizing Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Immunotherapy Picture
    Figure 9. Targeted Therapy Picture
    Figure 10. Chemotherapy Picture
    Figure 11. Hormone Therapy Picture
    Figure 12. Others Picture
    Figure 13. Global Personalizing Cancer Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 14. Global Personalizing Cancer Drugs Sales Value Market Share by Type, 2023 & 2030
    Figure 15. Product Picture of Breast Cancer
    Figure 16. Product Picture of Blood Cancer
    Figure 17. Product Picture of Gastrointestinal Cancer
    Figure 18. Product Picture of Prostate Cancer
    Figure 19. Product Picture of Skin Cancer
    Figure 20. Product Picture of Lung Cancer
    Figure 21. Product Picture of Others
    Figure 22. Global Personalizing Cancer Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 23. Global Personalizing Cancer Drugs Sales Value Market Share by Application, 2023 & 2030
    Figure 24. North America Personalizing Cancer Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 25. North America Personalizing Cancer Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 26. Europe Personalizing Cancer Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 27. Europe Personalizing Cancer Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 28. Asia Pacific Personalizing Cancer Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 29. Asia Pacific Personalizing Cancer Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 30. South America Personalizing Cancer Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 31. South America Personalizing Cancer Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 32. Middle East & Africa Personalizing Cancer Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 33. Middle East & Africa Personalizing Cancer Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 34. Key Countries/Regions Personalizing Cancer Drugs Sales Value (%), (2019-2030)
    Figure 35. United States Personalizing Cancer Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 36. United States Personalizing Cancer Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 37. United States Personalizing Cancer Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 38. Europe Personalizing Cancer Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 39. Europe Personalizing Cancer Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 40. Europe Personalizing Cancer Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 41. China Personalizing Cancer Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 42. China Personalizing Cancer Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 43. China Personalizing Cancer Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 44. Japan Personalizing Cancer Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 45. Japan Personalizing Cancer Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 46. Japan Personalizing Cancer Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 47. South Korea Personalizing Cancer Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 48. South Korea Personalizing Cancer Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 49. South Korea Personalizing Cancer Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 50. Southeast Asia Personalizing Cancer Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 51. Southeast Asia Personalizing Cancer Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 52. Southeast Asia Personalizing Cancer Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 53. India Personalizing Cancer Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 54. India Personalizing Cancer Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 55. India Personalizing Cancer Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 56. Personalizing Cancer Drugs Industrial Chain
    Figure 57. Personalizing Cancer Drugs Manufacturing Cost Structure
    Figure 58. Channels of Distribution (Direct Sales, and Distribution)
    Figure 59. Bottom-up and Top-down Approaches for This Report
    Figure 60. Data Triangulation

Description

The global market for Personalizing Cancer Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Personalizing Cancer Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Personalizing Cancer Drugs by region & country, by Type, and by Application.

The Personalizing Cancer Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Personalizing Cancer Drugs.

Market Segmentation